| Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics (NCT05985577) | Zhejiang Cancer Hospital | 2023-03-02 |
| Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites (NCT06046963) | Zhejiang Cancer Hospital | 2023-03-01 |
| Combined Screening for Gastrointestinal Tumors (NCT06478030) | Zhejiang Cancer Hospital | 2023-03-01 |
| Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer (NCT07014410) | Zhejiang Cancer Hospital | 2023-02-01 |
| A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma (NCT05705583) | Zhejiang Cancer Hospital | 2023-01-01 |
| PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients (NCT05651802) | Zhejiang Cancer Hospital | 2023-01-01 |
| Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer (NCT05669807) | Zhejiang Cancer Hospital | 2022-12-01 |
| A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status (NCT05669092) | Zhejiang Cancer Hospital | 2022-11-01 |
| Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC (NCT05550090) | Zhejiang Cancer Hospital | 2022-09-16 |
| SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC (NCT05652192) | Zhejiang Cancer Hospital | 2022-09-15 |
| Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency (NCT05461690) | Zhejiang Cancer Hospital | 2022-09-01 |
| TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors (NCT05544149) | Zhejiang Cancer Hospital | 2022-09-01 |
| Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study (NCT05480189) | Zhejiang Cancer Hospital | 2022-08-30 |
| Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer (NCT05564897) | Zhejiang Cancer Hospital | 2022-08-26 |
| A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure (NCT05489926) | Zhejiang Cancer Hospital | 2022-08-16 |
| A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy (NCT05559775) | Zhejiang Cancer Hospital | 2022-08-10 |
| Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC (NCT05507411) | Zhejiang Cancer Hospital | 2022-08-03 |
| Radiotherapy Combined With Endostatin and Capecitabine for NPC (NCT05514275) | Zhejiang Cancer Hospital | 2022-08-01 |
| ZR2 Sequential Immunochemotherapy for Newly Treated MCL (NCT05992597) | Zhejiang Cancer Hospital | 2022-08-01 |
| XPO-1 in Combination With RCHOP for DH/TH Lymphoma (NCT05974085) | Zhejiang Cancer Hospital | 2022-08-01 |
| Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery (NCT05448638) | Zhejiang Cancer Hospital | 2022-07-12 |
| DLCS for Predicting Neoadjuvant Chemotherapy Response (NCT05617469) | Zhejiang Cancer Hospital | 2022-07-01 |
| A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer (NCT05247619) | Zhejiang Cancer Hospital | 2022-06-30 |
| A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer (NCT05385809) | Zhejiang Cancer Hospital | 2022-06-01 |
| SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors (NCT05387044) | Zhejiang Cancer Hospital | 2022-05-01 |
| Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer (NCT05322499) | Zhejiang Cancer Hospital | 2022-04-15 |
| The 90% Effective Flow of High Flow Nasal Oxygenation (HFNO) During Sedated Bronchoscopy (NCT05298319) | Zhejiang Cancer Hospital | 2022-04-01 |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC (NCT05228496) | Zhejiang Cancer Hospital | 2022-03-17 |
| Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (NCT05856383) | Zhejiang Cancer Hospital | 2022-03-16 |
| H101 Combined With Camrelizumab for Recurrent Cervical Cancer (NCT05234905) | Zhejiang Cancer Hospital | 2022-03-01 |
| Retrospective Study of Brachytherapy (NCT05242861) | Zhejiang Cancer Hospital | 2022-02-20 |
| IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (NCT07493486) | Zhejiang Cancer Hospital | 2022-02-01 |
| HFNC and Hypoxia/Desaturation During Radiofrequency Ablation Under Moderate Sedation: A Randomized Clinical Trial (NCT05212064) | Zhejiang Cancer Hospital | 2022-01-01 |
| UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer (NCT05148767) | Zhejiang Cancer Hospital | 2022-01-01 |
| Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT05528367) | Zhejiang Cancer Hospital | 2022-01-01 |
| A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer (NCT05183958) | Zhejiang Cancer Hospital | 2021-12-31 |
| Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma (NCT05971199) | Zhejiang Cancer Hospital | 2021-11-23 |
| Immune Score Based Radiomics in Nasopharyngeal Carcinoma (NCT05126160) | Zhejiang Cancer Hospital | 2021-11-05 |
| PTC Guiding Neoadjuvant Treatment in Breast Cancer (NCT05103293) | Zhejiang Cancer Hospital | 2021-11-01 |
| ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL (NCT05290090) | Zhejiang Cancer Hospital | 2021-10-01 |
| Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer (NCT05160727) | Zhejiang Cancer Hospital | 2021-10-01 |
| Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma (NCT05053386) | Zhejiang Cancer Hospital | 2021-10-01 |
| Dendrobium Huoshanense Suppository in Rectal Cancer (NCT05079438) | Zhejiang Cancer Hospital | 2021-09-07 |
| The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer (NCT05075512) | Zhejiang Cancer Hospital | 2021-09-01 |
| Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics (NCT05269056) | Zhejiang Cancer Hospital | 2021-09-01 |
| Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer (NCT04974346) | Zhejiang Cancer Hospital | 2021-08-02 |
| HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis (NCT04889768) | Zhejiang Cancer Hospital | 2021-07-31 |
| A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC (NCT04967625) | Zhejiang Cancer Hospital | 2021-07-26 |
| Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases (NCT04808752) | Zhejiang Cancer Hospital | 2021-07-09 |
| RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer (NCT04972448) | Zhejiang Cancer Hospital | 2021-07-01 |
| Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC (NCT05007587) | Zhejiang Cancer Hospital | 2021-07-01 |
| Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms (NCT06078930) | Zhejiang Cancer Hospital | 2021-06-01 |
| A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma (NCT04860674) | Zhejiang Cancer Hospital | 2021-05-01 |
| Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study (NCT05054166) | Zhejiang Cancer Hospital | 2021-05-01 |
| Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients (NCT04858997) | Zhejiang Cancer Hospital | 2021-04-22 |
| Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer (NCT05991947) | Zhejiang Cancer Hospital | 2021-03-01 |
| A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor (NCT04691388) | Zhejiang Cancer Hospital | 2021-03-01 |
| Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer (NCT04665986) | Zhejiang Cancer Hospital | 2021-03-01 |
| A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer (NCT05030519) | Zhejiang Cancer Hospital | 2021-01-18 |
| Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC (NCT05131841) | Zhejiang Cancer Hospital | 2021-01-04 |
| Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy (NCT05468671) | Zhejiang Cancer Hospital | 2021-01-04 |
| Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma (NCT05232552) | Zhejiang Cancer Hospital | 2021-01-01 |
| Real World Study of Bone Metastases in Patients with Advanced Breast Cancer (NCT06873997) | Zhejiang Cancer Hospital | 2021-01-01 |
| Anterior Quadratus Lumborum Block at the Lateral Supra-arcuate Ligament for Analgesia After Open Liver Surgery (NCT04668391) | Zhejiang Cancer Hospital | 2020-12-17 |
| Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer (NCT04663763) | Zhejiang Cancer Hospital | 2020-12-01 |
| Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor (NCT05502458) | Zhejiang Cancer Hospital | 2020-12-01 |
| Anlotinib to Malignant Brainstem Glioma (NCT04668508) | Zhejiang Cancer Hospital | 2020-11-24 |
| Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) (NCT04255836) | Zhejiang Cancer Hospital | 2020-09-30 |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) (NCT04560751) | Zhejiang Cancer Hospital | 2020-09-30 |
| A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer (NCT04512417) | Zhejiang Cancer Hospital | 2020-08-31 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (NCT04506138) | Zhejiang Cancer Hospital | 2020-08-11 |
| A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) (NCT04446091) | Zhejiang Cancer Hospital | 2020-07-01 |
| Single Cell Sequencing Analysis of Thymoma (NCT04162691) | Zhejiang Cancer Hospital | 2020-06-06 |
| The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma (NCT04415385) | Zhejiang Cancer Hospital | 2020-06-01 |
| Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy (NCT04657848) | Zhejiang Cancer Hospital | 2020-06-01 |
| Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis (NCT04793672) | Zhejiang Cancer Hospital | 2020-05-01 |
| Rituximab Combined With Chidamide and Lenalidomide for r/r AITL (NCT04319601) | Zhejiang Cancer Hospital | 2020-03-13 |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer (NCT04135781) | Zhejiang Cancer Hospital | 2020-03-01 |
| Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC (NCT04189094) | Zhejiang Cancer Hospital | 2020-01-01 |
| Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer (NCT04300959) | Zhejiang Cancer Hospital | 2020-01-01 |
| Camrelizumab Combined With Local Treatment in NSCLC Patients With BM (NCT04291092) | Zhejiang Cancer Hospital | 2020-01-01 |
| Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study (NCT04190745) | Zhejiang Cancer Hospital | 2019-11-29 |
| Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC (NCT04161352) | Zhejiang Cancer Hospital | 2019-11-25 |
| Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy (NCT03638648) | Zhejiang Cancer Hospital | 2019-11-01 |
| Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen (NCT04191343) | Zhejiang Cancer Hospital | 2019-10-14 |
| A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. (NCT04084158) | Zhejiang Cancer Hospital | 2019-09-07 |
| TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients (NCT04066543) | Zhejiang Cancer Hospital | 2019-08-30 |
| Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma (NCT04049344) | Zhejiang Cancer Hospital | 2019-08-15 |
| A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma (NCT04061772) | Zhejiang Cancer Hospital | 2019-08-12 |
| CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer (NCT04121975) | Zhejiang Cancer Hospital | 2019-08-01 |
| Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer (NCT03756064) | Zhejiang Cancer Hospital | 2019-08-01 |
| Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (NCT04790409) | Zhejiang Cancer Hospital | 2019-08-01 |
| Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test (NCT04264468) | Zhejiang Cancer Hospital | 2019-05-14 |
| A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer (NCT03940001) | Zhejiang Cancer Hospital | 2019-05-01 |
| Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma (NCT04119674) | Zhejiang Cancer Hospital | 2019-03-19 |
| Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma (NCT03973008) | Zhejiang Cancer Hospital | 2019-03-11 |
| Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC (NCT03876587) | Zhejiang Cancer Hospital | 2019-03-01 |
| Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy (NCT03821454) | Zhejiang Cancer Hospital | 2019-02-01 |
| Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer (NCT03618810) | Zhejiang Cancer Hospital | 2019-01-20 |
| Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis (NCT03904225) | Zhejiang Cancer Hospital | 2018-12-14 |